Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
Cutaneous squamous cell carcinoma (cSCC) has an overall favourable outcome, except for patients with an advanced stage disease. The programmed death protein-1 (PD-1) inhibitor cemiplimab has been approved for use in advanced...
Read More